11.17 USD
▲+0.19+4.59%
盘后 10.50 -1.69%
2026-08-03
市值
$527.60M
市盈率
—
EPS
-1.59
股息率
—
52 周区间
4.19 – 12.19
成交量
518.58K
Beta
1.40
目标价
29.17
52W 低 4.1952W 高 12.19
价格走势
公司简介
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN3...